Scott et al., 2016 - Google Patents
Small molecules, big targets: drug discovery faces the protein–protein interaction challengeScott et al., 2016
View PDF- Document ID
- 7746275001914407340
- Author
- Scott D
- Bayly A
- Abell C
- Skidmore J
- Publication year
- Publication venue
- Nature Reviews Drug Discovery
External Links
Snippet
Protein–protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states. Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of …
- 230000004850 protein–protein interaction 0 title abstract description 143
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/16—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/70—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds
- G06F19/706—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds for drug design with the emphasis on a therapeutic agent, e.g. ligand-biological target interactions, pharmacophore generation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/22—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or SNP [Single-Nucleotide Polymorphism] discovery or sequence alignment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scott et al. | Small molecules, big targets: drug discovery faces the protein–protein interaction challenge | |
Wang et al. | Rational design of peptide-based inhibitors disrupting protein-protein interactions | |
Macalino et al. | Evolution of in silico strategies for protein-protein interaction drug discovery | |
Bhachoo et al. | Investigating protein–peptide interactions using the Schrödinger computational suite | |
Nero et al. | Oncogenic protein interfaces: small molecules, big challenges | |
Lao et al. | Rational design of topographical helix mimics as potent inhibitors of protein–protein interactions | |
Ibarra et al. | Predicting and experimentally validating hot-spot residues at protein–protein interfaces | |
Jubb et al. | Structural biology and drug discovery for protein–protein interactions | |
Raveh et al. | Sub‐angstrom modeling of complexes between flexible peptides and globular proteins | |
Villoutreix et al. | Drug‐Like Protein Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology | |
Winter et al. | Biophysical and computational fragment-based approaches to targeting protein–protein interactions: applications in structure-guided drug discovery | |
Falchi et al. | Structure-based design of small-molecule protein–protein interaction modulators: the story so far | |
Metz et al. | Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application | |
Rehman et al. | Computational approaches for the design of modulators targeting protein-protein interactions | |
Wanner et al. | Druggability assessment of protein–protein interfaces | |
Tan et al. | Benzene probes in molecular dynamics simulations reveal novel binding sites for ligand design | |
Bharatham et al. | Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study | |
Haider et al. | Combining solvent thermodynamic profiles with functionality maps of the Hsp90 binding site to predict the displacement of water molecules | |
Marchand et al. | Discovery of inhibitors of four bromodomains by fragment-anchored ligand docking | |
London et al. | Modeling peptide–protein interactions | |
Trisciuzzi et al. | Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery | |
Delaunay et al. | Computational tools and strategies to develop peptide-based inhibitors of protein-protein interactions | |
Han et al. | Development of QSAR‐Improved Statistical Potential for the Structure‐Based Analysis of Protein Peptide Binding Affinities | |
Tan et al. | Straightforward incorporation of multiple ligand types into molecular dynamics simulations for efficient binding site detection and characterization | |
Xu et al. | A computational investigation of small-molecule engagement of hot spots at protein–protein interaction interfaces |